

Marinomed Biotech AG

18.10.2019 – 17:00 Uhr

EANS-Voting Rights: Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

Notification of voting rights transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Overview

1. Issuer: Marinomed Biotech AG
2. Reason for the notification: Acquisition or disposal of voting rights
3. Person subject to notification obligation
Name: Erste Asset Management GmbH
City: Wien
Country: Österreich
4. Name of shareholder(s): Erste Asset Management GmbH
5. Date on which the threshold was crossed or reached: 18.10.2019
6. Total positions

	% of voting rights attached to shares (7.A)	% of voting rights through financial/instruments (7.B)	Total of both in % (7.A + 7.B)	Total number of voting rights of issuer (7.B.1 + 7.B.2)
Resulting situation on the date on which threshold was crossed / reached	7.71 %	0.00 %	7.71 %	1 469 772
Position of previous notification (if applicable)	0.00 %	0.00 %	0.00 %	

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares				
	Number of voting rights		% of voting rights	
	Direct	Indirect	Direct	Indirect
ISIN Code	(Sec 130 BörseG 2018)	(Sec 133 BörseG 2018)	(Sec 130 BörseG 2018)	(Sec 133 BörseG 2018)
ATMARINOMED6	113 317		7.71 %	
SUBTOTAL A	113 317		7.71 %	

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG 2018

Type of instrument	Expiration Date	Exercise Period	Number of voting rights that may be acquired if the instrument is exercised	% of voting rights
		SUBTOTAL B.1		

8. Information in relation to the person subject to the notification obligation:

9. In case of proxy voting

Voting rights after general meeting: - is equivalent to - voting rights.

The voting rights held by Erste Asset Management GmbH as stated in section 8 are not held directly but by the investment funds managed by the management company. They are therefore not holdings of the management company.

Note of the Issuer: This is a translation of the received shareholder notification in German language. The translation into English is not binding.

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
<http://www.marinomed.com>

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
<http://www.metrum.at>

end of announcement euro adhoc

mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Original content of: Marinomed Biotech AG, transmitted by news aktuell

Diese Meldung kann unter <https://www.presseportal.de/en/pm/132651/4408300> abgerufen werden.